Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

TROP-2-Directed ADC Could Be New Standard for Some NSCLCs.

Created on 14 Nov 2026

Published in

Cancer discovery. Pages OF1. Nov 14, 2026. Epub Nov 14, 2026.

Abstract

In the phase III Opti-TROP-Lung06 trial, patients with newly diagnosed PD-L1-negative, advanced nonsquamous non-small cell lung cancer without targetable alterations who received the TROP-2-directed antibody-drug conjugate sacituzumab tirumotecan and the PD-1 inhibitor pembrolizumab experienced a median progression-free survival (PFS) of 15 months. In comparison, those patients who received standard chemotherapy plus pembrolizumab experienced a median PFS of 5.7 months.

PMID:
43031331
Bibliographic data and abstract were imported from PubMed on 14 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 9
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement